• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LC-MS/MS determination of Synercid injections.

作者信息

Abdel-Hamid Mohammed E, Phillips Oludotun A

机构信息

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Health Sciences Center, Kuwait University, PO Box 24923, 13110, Safat, Kuwait.

出版信息

J Pharm Biomed Anal. 2003 Aug 21;32(6):1167-74. doi: 10.1016/s0731-7085(03)00231-0.

DOI:10.1016/s0731-7085(03)00231-0
PMID:12907260
Abstract

Synercid is a combination of two semisynthetic pristinamycin derivatives, quinupristin and dalfopristin in 30:70 (w/w) ratio. A rapid and specific high-performance liquid chromatography-mass spectrometry was developed for the determination of quinupristin and dalfopristin using positive electrospray tandem mass spectrometry (+ESI-MS/MS). Multiple reaction monitoring transitions at 1023.05>134.34 and 691.87>166.26 were selected for the quantitation of quinupristin and dalfopristin, respectively. The assay run cycle-time was approximately 2.0 min injection-to-injection. The assay was linear up to concentration of 4000 ng x ml(-1) quinupristin and 1920 ng x ml(-1) dalfopristin. The lowest limits of quantitation of quinupristin and dalfopristin were found to be 1000 and 480 ng x ml(-1), respectively. Quantitation was based on peak area measurement of quinupristin and dalfopristin using weighed linear regression. Linear relationships with correlation coefficients (r>0.99) were automatically computed for both constituents by MASSLYNX quantify program. The ratio of the slopes of the calibration curves of quinupristin and dalfopristin was found to be 0.425, which matches the nominal ratio composition of the antimicrobial compounds in Synercid. The %RSD ranges were 2.3-4.0% for dalfopristin and 1.3-4.2% for quinupristin, whereas the %DEV ranges were (-7.5+3.7) and (-1.2+9.1%), respectively, indicating appropriate precision and accuracy. Recoveries of 99.5-103.8% and 97.8-99.0% of quinupristin and dalfopristin, respectively, were computed from Synercid injection. The described method is recommended for rapid determination of the contents and for tracking the stability and compatibility of quinupristin and dalfopristin in Synercid injection.

摘要

相似文献

1
LC-MS/MS determination of Synercid injections.
J Pharm Biomed Anal. 2003 Aug 21;32(6):1167-74. doi: 10.1016/s0731-7085(03)00231-0.
2
Simultaneous high-performance liquid chromatographic determination of quinupristin, dalfopristin and their main metabolites in human plasma.
J Chromatogr B Biomed Sci Appl. 1998 Apr 24;708(1-2):161-8. doi: 10.1016/s0378-4347(98)00005-x.
3
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.住院的复杂性革兰氏阳性皮肤及皮肤结构感染患者的治疗:两项关于奎奴普丁/达福普汀对比头孢唑林、苯唑西林或万古霉素的随机、多中心研究。链阳霉素皮肤及皮肤结构感染研究组。
J Antimicrob Chemother. 1999 Aug;44(2):263-73. doi: 10.1093/jac/44.2.263.
4
Clinical pharmacokinetics of quinupristin/dalfopristin.奎奴普丁/达福普汀的临床药代动力学
Clin Pharmacokinet. 2004;43(4):239-52. doi: 10.2165/00003088-200443040-00003.
5
In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).奎奴普丁/达福普汀(Synercid)的体外活性及抗生素后效应
Chemotherapy. 2001 Jul-Aug;47(4):243-9. doi: 10.1159/000048530.
6
Quinupristin-dalfopristin is active against Toxoplasma gondii.奎奴普丁-达福普汀对刚地弓形虫具有活性。
Antimicrob Agents Chemother. 1999 Aug;43(8):2043-5. doi: 10.1128/AAC.43.8.2043.
7
Liquid chromatographic-electrospray tandem mass spectrometric determination of clarithromycin in human plasma.液相色谱-电喷雾串联质谱法测定人血浆中的克拉霉素
Biomed Chromatogr. 2006 Nov;20(11):1242-51. doi: 10.1002/bmc.691.
8
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.奎奴普丁/达福普汀:用于治疗严重革兰氏阳性菌感染的综述
Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008.
9
In vitro activity of quinupristin/dalfopristin (Synercid, RP 59500) against Legionella spp.
Diagn Microbiol Infect Dis. 2000 Jan;36(1):49-52. doi: 10.1016/s0732-8893(99)00107-8.
10
Quantitative determination of zidovudine diaryl phosphate triester pro-drugs in rat plasma by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry.高效液相色谱-电喷雾电离串联质谱法对大鼠血浆中齐多夫定二芳基磷酸三酯前体药物的定量测定
J Pharm Biomed Anal. 2008 Dec 15;48(5):1417-24. doi: 10.1016/j.jpba.2008.11.023. Epub 2008 Nov 27.

引用本文的文献

1
The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis.全球达托霉素、替加环素、奎奴普丁/达福普汀和利奈唑胺耐药金黄色葡萄球菌和凝固酶阴性葡萄球菌菌株的流行情况:系统评价和荟萃分析。
Antimicrob Resist Infect Control. 2020 Apr 22;9(1):56. doi: 10.1186/s13756-020-00714-9.
2
Probing the molecular mechanisms for pristinamycin yield enhancement in Streptomyces pristinaespiralis.探究螺旋霉素产量提高的分子机制在吸水链霉菌。
Curr Microbiol. 2012 Dec;65(6):792-8. doi: 10.1007/s00284-012-0233-1. Epub 2012 Sep 19.